ImmunityBio, Inc. (IBRX) Stock
2 members of Congress disclosed 3 trades in IBRX since 2023: 2 purchases and 1 sale, most recently Lisa McClain (purchase, Sep 30, 2026). 6 of the hedge funds AlphaScala tracks reported IBRX in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is D.E. Shaw's at $101.13M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 6, 2026.
Which members of Congress traded ImmunityBio, Inc. (IBRX)?
Most recent: Lisa McClain (purchase, Sep 30, 2026); records start Mar 6, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2026-09-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2026-09-28 | purchase | $1k – $15k |
| Dan Goldman D-NY · House | 2023-03-06 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all IBRX political trades →Which hedge funds own IBRX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 11.55M | $101.13M | -8% |
| Millennium Management Israel Englander | 5.58M | $48.85M | +293% |
| Renaissance Technologies Jim Simons (founder) | 1.03M | $9.01M | NEW |
| Marshall Wace | 388K | $3.40M | +403% |
| Hussman Investment Trust John Hussman | 210K | $1.98M | +43% |
| Citadel Ken Griffin | 136K | $1.19M | -55% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are ImmunityBio, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 5, 26 | Simon Barry J. | Director | SELL | 25.0K | $269K |
| Oct 2, 26 | Cohen Cheryl | Director | SELL | 81.1K | $851K |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →IBRX price chart
Powered by TradingViewWhat does ImmunityBio, Inc. do?
ImmunityBio, Inc. is a commercial-stage biotechnology company dedicated to developing and commercializing next-generation immunotherapies that harness the body's innate and adaptive immune systems to combat cancer and infectious diseases. Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an FDA-approved interleukin-15 superagonist used in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company operates a vertically integrated model, controlling processes from discovery and research through manufacturing and commercialization via its proprietary BioShield platform, which includes cytokine fusion proteins, cell therapies, DNA vaccines, and recombinant BCG to address supply shortages. ImmunityBio maintains a robust clinical pipeline targeting solid and liquid tumors, such as non-small cell lung cancer and glioblastoma, as well as infectious diseases. Founded in 2014 and headquartered in Morrisville, North Carolina, ImmunityBio focuses on patient-centric innovations that augment natural killer cells, T-cells, macrophages, and dendritic cells for durable immune responses.